HC Wainwright Reaffirms “Buy” Rating for Altimmune (NASDAQ:ALT)

Altimmune (NASDAQ:ALT)‘s stock had its “buy” rating reaffirmed by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $12.00 target price on the stock. HC Wainwright’s price target suggests a potential upside of 160.30% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Stifel Nicolaus started coverage on Altimmune in a research note on Wednesday, January 8th. They set a “buy” rating and a $18.00 target price for the company. William Blair reiterated a “market perform” rating on shares of Altimmune in a research note on Friday, March 14th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Trading Down 3.6 %

Altimmune stock traded down $0.17 during trading hours on Thursday, reaching $4.61. 1,152,303 shares of the company were exchanged, compared to its average volume of 2,918,279. Altimmune has a 12 month low of $4.48 and a 12 month high of $11.16. The stock has a 50-day moving average of $6.12 and a 200 day moving average of $7.00. The firm has a market cap of $355.03 million, a price-to-earnings ratio of -2.97 and a beta of 0.87.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, February 27th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. As a group, research analysts forecast that Altimmune will post -1.35 EPS for the current year.

Insider Transactions at Altimmune

In related news, CFO Gregory L. Weaver bought 10,000 shares of the company’s stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $5.20 per share, with a total value of $52,000.00. Following the acquisition, the chief financial officer now owns 10,000 shares in the company, valued at approximately $52,000. This represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by insiders.

Institutional Trading of Altimmune

Large investors have recently bought and sold shares of the stock. SBI Securities Co. Ltd. bought a new position in shares of Altimmune during the fourth quarter valued at $45,000. Virtus ETF Advisers LLC acquired a new stake in shares of Altimmune during the 4th quarter worth about $60,000. Cullen Frost Bankers Inc. bought a new position in Altimmune during the 4th quarter valued at about $72,000. 180 Wealth Advisors LLC acquired a new position in Altimmune in the fourth quarter valued at about $78,000. Finally, Sunbelt Securities Inc. grew its stake in Altimmune by 356.8% during the fourth quarter. Sunbelt Securities Inc. now owns 10,844 shares of the company’s stock worth $79,000 after buying an additional 8,470 shares during the last quarter. 78.05% of the stock is currently owned by institutional investors.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.